陨石试验:托珠单抗和糖皮质激素诱导缓解后甲氨蝶呤治疗巨细胞动脉炎的疗效——一项随机双盲安慰剂对照平行组II期研究方案
该II期试验拟纳入40例经糖皮质激素和至少6个月托珠单抗治疗达到稳定缓解的巨细胞动脉炎患者,按1:1随机接受每周皮下注射17.5 mg甲氨蝶呤或安慰剂治疗12个月,主要终点为治疗期间首次复发时间,旨在评估甲氨蝶呤维持缓解的疗效与安全性。
要点
- 糖皮质激素是巨细胞动脉炎标准治疗,但不良反应多、复发率高。
- 托珠单抗可维持缓解并减少糖皮质激素累积剂量,但停药后仅约半数患者维持缓解。
- 甲氨蝶呤已证实可降低新发巨细胞动脉炎复发风险,本研究评估其用于托珠单抗后维持缓解。
核心结论
- 这是首个评估巨细胞动脉炎患者经托珠单抗治疗周期后使用甲氨蝶呤维持缓解的临床试验;托珠单抗停用后,甲氨蝶呤可能是一种安全且廉价的药物。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照、平行组II期试验,随机纳入40例巨细胞动脉炎患者,按1:1分为甲氨蝶呤组或安慰剂组。
- 入组患者此前接受糖皮质激素和至少6个月托珠单抗治疗并达到稳定缓解。
- 甲氨蝶呤组每周皮下注射17.5 mg甲氨蝶呤,安慰剂组注射匹配安慰剂,治疗12个月,临床需要时可减量,随后随访6个月。
主要发现
- 主要终点为12个月治疗期间甲氨蝶呤组与安慰剂组首次复发的时间。
- 次要结局包括患者报告和研究者报告的结局、实验室检查结果,以及研究期间主动脉炎患病率、受累血管数量和内膜中层厚度变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glucocorticoids (GC) are the standard treatment for giant cell arteritis (GCA), even though they are associated with adverse side effects and high relapse rates. Tocilizumab (TCZ), an interleukin-6 receptor antagonist, has shown promise in sustaining remission and reducing the cumulative GC dosage, but it increases the risk of infections and is expensive. After discontinuation of TCZ, only about half of patients remain in remission. Additionally, only few studies have been conducted looking at remission maintenance, highlighting the need for alternative strategies to maintain remission in GCA. Methotrexate (MTX) has been shown to significantly decrease the risk of relapse in new-onset GCA and is already a proven safe drug in many rheumatologic diseases. METHODS: This study aims to evaluate the efficacy and safety of MTX in maintaining remission in patients with GCA who have previously been treated with GC and at least 6 months with TCZ. We hypothesize that MTX can maintain remission in GCA patients, who have achieved stable remission after treatment with GC and TCZ, and prevent the occurrence of relapses. The study design is a monocentric, randomized, double-blind, placebo-controlled, parallel-group phase II trial randomizing 40 GCA patients 1:1 into a MTX or placebo arm. Patients will receive 17.5 mg MTX/matching placebo weekly by subcutaneous injection for 12 months, with the possibility of dose reduction if clinically needed. A 6-month follow-up will take place. The primary endpoint is the time to first relapse in the MTX group versus placebo during the 12-month treatment period. Secondary outcomes include patient- and investigator-reported outcomes and laboratory findings, as well as the prevalence of aortitis, number of vasculitic vessels, and change in intima-media thickness during the study. DISCUSSION: This is the first clinical trial evaluating remission maintenance of GCA with MTX after a previous treatment cycle with TCZ. Following the discontinuation of TCZ in GCA, MTX could be a safe and inexpensive drug. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05623592. Registered on 21 November 2022. EU Clinical Trials Register, 2022-501058-12-00. German Clinical Trials Register DRKS00030571.
引用
- Kreis L, Dejaco C, Schmidt WA, et al. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study. Trials. 2024. PMID: 38225579. doi:10.1186/s13063-024-07905-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。